title: Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab.
authors.affiliation: Rush University Medical Center Chicago, Ill, USA. aileen_go@rush.edu
authors.forename: Aileen
authors.initials: A
authors.lastname: Go
authors.forename: Parameswaran
authors.initials: P
authors.lastname: Venugopal
authors.forename: Jerome
authors.initials: J
authors.lastname: Loew
authors.forename: Dragan
authors.initials: D
authors.lastname: Djordjevic
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D002490:Central Nervous System / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed / Q000379:methods; D016896:Treatment Outcome; D019043:Vascular Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab